Skip to main content

Table 3 Healthcare utilization and medical costs of patients with ATTR-CM (PPPM)

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

 

Pre-cohort entry date,

mean (SD)

Post-cohort entry date, mean (SD)

P-value

Number of inpatient admissions

0.10 (0.12)

0.38 (0.55)

< 0.001

 ER

0.01 (0.03)

0.03 (0.11)

0.040

 ICU

0.01 (0.04)

0.09 (0.27)

< 0.001

Length of hospital stay (days)

1.12 (2.78)

5.72 (9.08)

< 0.001

Number of outpatient visits

2.63 (2.10)

2.60 (1.96)

0.837

 ER

0.02 (0.06)

0.05 (0.25)

0.085

Follow-up costs

$400 ($588)

$1864 ($2773)

< 0.001

 Inpatient

$313 ($567)

$1730 ($2767)

< 0.001

 Outpatient

$87 ($76)

$134 ($154)

< 0.001

  1. ATTR-CM Transthyretin amyloid cardiomyopathy, ER Emergency room, ICU Intensive care unit, PPPM Per patient per month, SD Standard deviation